Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.

Title	Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.
Publication Type	Journal Article
Year of Publication	2024
Authors	Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P, Christos PJ, Saxena A, Elemento O, Bhinder B, Ager C, Amin ADipak, Sanfilippo NJ, Mittal V, Borczuk AC, Formenti SC, Izar B, McGraw TE
Journal	Nat Commun
Volume	15
Issue	1
Pagination	225
Date Published	2024 Jan 03
ISSN	2041-1723
DOI	10.1038/s41467-023-44575-3
Alternate Journal	Nat Commun
PubMed ID	38172131
PubMed Central ID	PMC10764801